Ney Carter Borges: Pulse Pressure as an Integrated Marker of Arterial Stiffness and Cardiovascular Risk
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
”Pulse Pressure as an Integrated Marker of Arterial Stiffness and Cardiovascular Risk
Pulse pressure (PP), defined as the difference between systolic and diastolic blood pressure, has emerged as a clinically meaningful biomarker that extends beyond traditional blood pressure parameters.
Rather than being a simple arithmetic derivative, PP reflects the interplay between arterial stiffness, vascular compliance, and left ventricular ejection dynamics, making it a powerful integrator of cardiovascular physiology.
Evidence from landmark studies consistently demonstrates its prognostic value. In the Framingham Heart Study, each 10 mmHg increase in PP was associated with a significant rise in coronary heart disease risk, independent of mean arterial pressure.
Similarly, observational cohorts and meta-analyses have confirmed that elevated PP is strongly associated with cardiovascular mortality, stroke, and heart failure, particularly in aging populations where arterial stiffening predominates.
Mechanistically, increased PP reflects reduced elasticity of large arteries, leading to earlier wave reflection and amplification of systolic pressure. This results in increased myocardial oxygen demand, impaired coronary perfusion during diastole, and progressive endothelial dysfunction.
Over time, these effects contribute to atherosclerotic progression and target-organ damage, including renal and cerebral injury.
From an evidence-based perspective, several consistent patterns emerge. First, elevated PP is a robust marker of arterial stiffness, a central driver of cardiovascular risk. Second, each 10 mmHg increment in PP is associated with an approximate 10–25% increase in cardiovascular risk, depending on the population studied.
Third, PP shows strong and independent associations with major clinical outcomes, including coronary artery disease, stroke, heart failure, and all-cause mortality. Notably, in older hypertensive patients, PP may outperform mean arterial pressure as a predictor of adverse events.
Importantly, PP demonstrates a nonlinear (J-shaped) relationship with outcomes. While high PP (>60 mmHg) reflects vascular aging and increased pulsatile load, very low PP (<30 mmHg) may indicate reduced stroke volume or advanced cardiac dysfunction, particularly in heart failure or shock states.
Clinically, PP provides incremental value in risk stratification when interpreted alongside systolic and diastolic pressures. It serves as a functional marker of vascular aging and subclinical organ damage, offering practical insight into patient prognosis.”
Other posts featuring Ney Carter Borges on Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers